Imaging glial activation in patients with post-treatment Lyme disease symptoms: A pilot study using [ 11 C]DPA-713 PET

Jennifer M. Coughlin, Ting Yang, Alison W. Rebman, Kathleen T. Bechtold, Yong Du, William B. Mathews, Wojciech G. Lesniak, Erica A. Mihm, Sarah M. Frey, Erica S. Marshall, Hailey B. Rosenthal, Tristan A. Reekie, Michael Kassiou, Robert F. Dannals, Mark J. Soloski, John N. Aucott, Martin G. Pomper

Research output: Contribution to journalArticlepeer-review

Abstract

The pathophysiology of post-treatment Lyme disease syndrome (PTLDS) may be linked to overactive immunity including aberrant activity of the brain's resident immune cells, microglia. Here we used [ 11 C]DPA-713 and positron emission tomography to quantify the 18 kDa translocator protein, a marker of activated microglia or reactive astrocytes, in the brains of patients with post-treatment Lyme disease symptoms of any duration compared to healthy controls. Genotyping for the TSPO rs6971 polymorphism was completed, and individuals with the rare, low affinity binding genotype were excluded. Data from eight brain regions demonstrated higher [ 11 C]DPA-713 binding in 12 patients relative to 19 controls. [ 11 C]DPA-713 PET is a promising tool to study cerebral glial activation in PTLDS and its link to cognitive symptoms.

Original languageEnglish (US)
Article number346
JournalJournal of Neuroinflammation
Volume15
Issue number1
DOIs
StatePublished - Dec 19 2018

Keywords

  • Microglia
  • Neuroimaging
  • Post-treatment Lyme disease syndrome
  • [ C]DPA-713

ASJC Scopus subject areas

  • Neuroscience(all)
  • Immunology
  • Neurology
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Imaging glial activation in patients with post-treatment Lyme disease symptoms: A pilot study using [ <sup>11</sup> C]DPA-713 PET'. Together they form a unique fingerprint.

Cite this